Mark W Karwal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8834355/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncology, The, 2018, 19, 940-952.	10.7	1,816
2	Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2011, 17, 1973-1983.	7.0	142
3	Tracheobronchial amyloidosis: A surgical disease with long-term consequences. Journal of Thoracic and Cardiovascular Surgery, 2004, 128, 789-792.	0.8	26
4	Effects of Intravenous Amino Acid Administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTherâ,,¢]) Treatment. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 35-41.	1.0	19
5	Assessment of Hepatic Toxicity from Treatment with 90Y-SMT 487 (OctreoTherâ,"¢) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 581-588.	1.0	14
6	Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies. Breast, 2012, 21, 89-94.	2.2	12
7	Durable responses to rituximab in acquired factor VIII deficiency. Thrombosis and Haemostasis, 2011, 106, 172-174.	3.4	10
8	The Role of Radionuclide Angiocardiography in the Treatment of Patients Receiving Doxorubicin-Based Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 132-137.	1.3	6
9	A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer, 2010, 116, NA-NA.	4.1	4